XENE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
120.1M
-2.5%
123.2M
+9.6%
112.3M
+2.3%
109.8M
+13.9%
96.3M
R&D
95.6M
-3.6%
99.2M
+12.1%
88.5M
+0.9%
87.7M
+13.8%
77.1M
SG&A
24.4M
+2.1%
23.9M
+0.5%
23.8M
+7.9%
22.1M
+14.4%
19.3M
Operating Income
-120067000
+2.5%
-123155000
-9.6%
-112328000
-2.3%
-109767000
-13.9%
-96336000
EBITDA
-119505000
+2.5%
-122597000
-9.7%
-111741000
-2.4%
-109156000
-14.1%
-95695000
Net Income
-110435000
+0.3%
-110736000
-8.2%
-102302000
+2.8%
-105261000
-15.8%
-90896000
EPS (Basic)
$-1.11
+0.0%
$-1.11
+5.1%
$-1.17
+10.7%
$-1.31
-13.9%
$-1.15
EPS (Diluted)
$-1.11
+0.0%
$-1.11
+5.1%
$-1.17
+10.7%
$-1.31
-13.9%
$-1.15
Shares (Diluted)
99.8M
+0.2%
99.6M
+14.0%
87.3M
+9.0%
80.1M
+1.1%
79.2M
Xenon Pharmaceuticals (XENE) — Financials